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Background: To support patients with COPD in their self-management of symptom worsening, 
we developed Adaptive Computerized COPD Exacerbation Self-management Support 
(ACCESS), an innovative software application that provides automated treatment advice without 
the interference of a health care professional. Exacerbation detection is based on 12 symptom-
related yes-or-no questions and the measurement of peripheral capillary oxygen saturation 
(SpO
2
), forced expiratory volume in one second (FEV
1
), and body temperature. Automated 
treatment advice is based on a decision model built by clinical expert panel opinion and Bayes-
ian network modeling. The current paper describes the validity of ACCESS.
Methods: We performed secondary analyses on data from a 3-month prospective observational 
study in which patients with COPD registered respiratory symptoms daily on diary cards and 
measured SpO
2
, FEV
1
, and body temperature. We examined the validity of the most important 
treatment advice of ACCESS, ie, to contact the health care professional, against symptom- and 
event-based exacerbations.
Results: Fifty-four patients completed 2,928 diary cards. One or more of the different pieces 
of ACCESS advice were provided in 71.7% of all cases. We identified 115 symptom-based 
exacerbations. Cross-tabulation showed a sensitivity of 97.4% (95% CI 92.0–99.3), specificity 
of 65.6% (95% CI 63.5–67.6), and positive and negative predictive value of 13.4% (95% CI 
11.2–15.9) and 99.8% (95% CI 99.3–99.9), respectively, for ACCESS’ advice to contact a 
health care professional in case of an exacerbation.
Conclusion: In many cases (71.7%), ACCESS gave at least one self-management advice to 
lower symptom burden, showing that ACCES provides self-management support for both day-
to-day symptom variations and exacerbations. High sensitivity shows that if there is an exac-
erbation, ACCESS will advise patients to contact a health care professional. The high negative 
predictive value leads us to conclude that when ACCES does not provide the advice to contact 
a health care professional, the risk of an exacerbation is very low. Thus, ACCESS can safely 
be used in patients with COPD to support self-management in case of an exacerbation.
Keywords: COPD, exacerbations, telehealth, software application, treatment advice, self-
management, health, mobile health, automated device, diagnostic accuracy
Introduction
COPD is a heterogeneous disease with fluctuations in daily respiratory symptoms. 
Many patients with COPD suffer from acute exacerbations. These episodes are defined 
as “sustained worsening of the patient’s condition from the stable state, and beyond 
normal day-to-day variations, that are acute in onset and necessitate a change in regular 
medication”.1 Exacerbations pose a substantial burden on patients and society, since 
they are the main cause of hospitalization,2 mortality,3 and health care utilization4 in 
COPD, and lead to a more rapid decline in lung function5,6 and health status.6–8
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When exacerbations are treated promptly, recovery time9,10 
and hospital admissions10,11 can be reduced. However, many 
patients poorly recognize the difference between regular 
day-to-day variations and exacerbations and do not respond to 
an imminent exacerbation adequately.8,9,11 Self-management 
programs that include patient education and the use of written 
action plans have been developed to improve patients’ self-
management behavior at times of an exacerbation. A written 
action plan contains instructions about the medication to use 
and the actions to take when a patient notices that respira-
tory symptoms worsen. Research has shown that the use of 
written action plans may enhance prompt treatment of exac-
erbations and, as a result, improve health-related quality of 
life,12 reduce recovery time9,13–15 and hospital admissions.12,16,17 
Therefore, current clinical COPD guidelines recommend a 
written exacerbation action plan for every COPD patient 
with frequent exacerbations to keep at home.18,19 However, 
it has been reported that in ~50% of exacerbations, patients 
do not adhere to the instructions in the action plan.9 Exacer-
bation self-management appears to be negatively influenced 
by habituation to symptoms, heterogeneity of exacerbations, 
low self-empowerment, and patients’ belief that they should 
not bother others with their problems.20,21
To optimize patients’ self-management during symptom 
worsening that may indicate an exacerbation in development, 
there is a need for easy-to-use tools to better support patients 
in the recognition and interpretation of symptoms than a paper 
action plan does, and to further improve self-empowerment 
and stimulate a sense of urgency to seek medical treatment, 
when needed. Therefore, we have previously developed a 
software application called “Adaptive Computerized COPD 
Exacerbation Self-management Support” (ACCESS).22 This 
software application aims to 1) identify exacerbations in an 
early phase and 2) directly provide self-management advice 
without the intervention of a health care professional. The 
advice enables patients to take prompt and adequate action 
in case of an imminent exacerbation. In this study, we deter-
mined whether patients with COPD can safely use ACCESS 
as a self-management support tool in case of symptom wors-
ening. More specifically, our research question was “What is 
the validity, expressed as sensitivity, specificity, positive and 
negative predictive value, of ACCESS’ clinically most impor-
tant advice, ie, to contact a health care professional today, 
which is given when a COPD exacerbation is imminent?”
Methods
study design, population, and sample size
We performed secondary analyses on data that were 
obtained in a 3-month prospective observational study 
that was designed to cross-validate the Bayesian network 
model (Supplementary materials). Patients with COPD 
were recruited from the outpatient clinic and the pulmonary 
rehabilitation program of the Radboud University Medical 
Center, Dekkerswald (Nijmegen, the Netherlands). Patients 
were eligible if they had a spirometry-confirmed diagnosis 
of COPD (ie, post-bronchodilator FEV
1
/FVC ,0.7), were 
known by their health care professional to have a high exacer-
bation risk, were able to communicate in the Dutch language, 
and were not familiar with physical or mental problems that 
would prevent adherence to study protocol. Additionally, 
in the outpatient population, patients had to be able to visit 
Dekkerswald if their symptoms worsened. At the pulmonary 
rehabilitation center, eligible patients received oral and 
written information about the study from a research team 
member. In the outpatient clinic, eligible patients received a 
written invitation to participate from their pulmonary nurse. 
After a week, patients who agreed to participate received 
individual oral and written instructions from a member of 
the research team. Within the inclusion period, patients 
from the outpatient clinic were invited to participate in sets, 
simultaneous to the consecutive inclusion of patients from 
the rehabilitation program. No formal sample size calcula-
tion was performed, but 50 exacerbations were considered 
sufficient for the cross-validation of the Bayesian network 
model (Supplementary material). In previous research in 
this patient population, an average of 4.2 exacerbations per 
year per patient was observed,23 so, theoretically, 50 patients 
would need to participate for 3 months to reach the number 
of 50 exacerbations.
Written informed consent was obtained from all the par-
ticipating patients. The Medical Ethics Committees of the 
regions Arnhem and Nijmegen approved the study (approval 
number 2013/385).
aCCess software application
ACCESS is an innovative automated exacerbation self-
management support system. The system is innovative as it 
combines exacerbation detection with automated treatment 
advice without the interference of a health care professional. 
Exacerbation detection is based on the results of 12 yes-
or-no questions about worsening of symptoms, emotions, 
and bronchodilator use and the outcomes of measurement of 
peripheral capillary oxygen saturation (SpO
2
 in %, Contec 
Pulse Oximeter, CMS50D), FEV
1
 (in liters, Vitalograph 
asma-1), and body temperature (in degrees Celsius, Medisana 
FTN infrared thermometer) (Figure 1). After data recording 
and depending on the outcomes, ACCESS directly generates 
1–6 automated treatment options to support self-management 
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to alleviate symptom burden. In case the responses to the 
questions and/or the measurements indicate an imminent/
possible exacerbation, ACCESS always advises to use the 
system again the next day. Which advice ACCESS will give 
is based on a decision tree that was designed by an expert 
panel of clinicians (Figure 2) and the risk of an exacerbation 
as predicted from a Bayesian network model that is incorpo-
rated in ACCESS.22 The system is adaptive in the sense that 
it is personalized by the patient’s health care professional, 
who sets personal reference values for FEV
1
 and SpO
2
, inserts 
patient-specific medication instructions, and decides on 
which pieces of advice are relevant for the patient. We refer 
to the supplementary file for more details about the develop-
ment, content, and evaluation of the system.
Data collection
During the 3-month follow-up, patients completed paper 
diary cards with the 12 ACCESS questions and three physi-
ological measurements (SpO
2
, FEV
1
, and body temperature; 
Supplementary material) every day. All data were gathered 
on paper to prevent missing data due to difficulty in the use 
of the software. The diary cards were collected weekly. The 
automated treatment advice was calculated by the ACCESS 
computer model after the 3-month observation period for 
each entry and added to the study database (see Figure 2 for 
the decision model).
Patients were instructed to contact their chest physician 
or respiratory nurse every time they had a worsening of any 
respiratory symptom. The chest physician diagnosed whether 
an exacerbation was present or not and recorded diagnosis 
and treatment plan on a standardized form. Additionally, 
at the end of follow-up, the patients’ medical records were 
examined in detail by the investigators (LB, EB) for exac-
erbation occurrences.
Furthermore, each patient completed a separate “best 
value” form on a stable day together with a health care 
professional or an investigator (LB) to establish the refer-
ence values for the patient’s personal best measurements of 
FEV
1
 and SpO
2
.
exacerbations
We used a symptom-based and an event-based definition 
of exacerbations to compare ACCESS’ advice to contact a 
health care professional with.
1. Symptom-based definition: the diary card data were 
used to identify symptom-based exacerbations using the 
following definition: a change for at least 2 consecutive 
days in two or more major symptoms (dyspnea, sputum 
purulence, sputum amount), or a change in any one 
major symptom plus one or more minor symptoms (cold, 
wheeze, sore throat, cough).5,24,25
 We counted a new exacerbation episode when it was 
preceded by at least 2 days without exacerbation.
2. Event-based definition: all contacts documented by 
health care professionals that led to a new prescription 
of prednisolone and/or antibiotics or hospitalization were 
considered event-based exacerbations.
statistical analyses
Missing diary card data were excluded from analyses, since 
on a day with missing data, ACCESS cannot determine 
Figure 1 Content of aCCess.
Abbreviations: aCCess, adaptive Computerized COPD exacerbation self-management support; spO2, peripheral capillary oxygen saturation; FeV1, forced expiratory 
volume in one second.
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whether or not one or more pieces of advice should be given. 
We used descriptive statistics to examine the occurrence of 
the 6 automated pieces of advice. When an exacerbation 
was imminent, ACCESS should have advised patients to 
contact a health care professional. So, because of the clinical 
importance, we examined the relationship between ACCESS’ 
advice to contact a health care professional and symptom-
based exacerbations with cross-tabulations. Sensitivity, 
specificity, and positive and negative predictive values were 
calculated. To consider ACCESS as being safe, sensitivity 
should be high (ie, if an exacerbation is indeed present, 
ACCESS should advise to contact a health care professional 
in virtually all cases), and negative predictive value should 
be high (ie, if ACCESS does not advise to contact a health 
care professional, there should be no exacerbation in virtually 
all cases). We looked at the second day of each exacerba-
tion episode, because we wanted to examine if ACCESS 
provides timely advice, and this was the first day that an 
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????
????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????? ?????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
?????????????? ??????????????
??????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????? ???????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
?????????????????????
???????????????????????????????????????????
???????????????????????????
????????????????????????????
??????????????????????????????????????????????
????????????????????????????????????????????????????
????????????????????????
Figure 2 expert decision model of aCCess advice.
Abbreviations: aCCess, adaptive Computerized COPD exacerbation self-management support; spO2, peripheral capillary oxygen saturation; FeV1, forced expiratory 
volume in one second.
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exacerbation could actually be established according to our 
definition.5,24,25 We performed post hoc descriptive analyses 
to further explore the precise reasons behind ACCESS’ 
advice to contact a health care professional in the absence 
of a symptom-based exacerbation.
To compare ACCESS’ advice to contact a health care 
professional to the actual diagnosis of the health care profes-
sionals, the ACCESS advice was also cross-tabulated with 
event-based exacerbations. Again, sensitivity, specificity, and 
positive and negative predictive values were calculated.
IBM Statistical Package for Social Sciences (SPSS) 22 
was used for all analyses.
Results
Patients and exacerbations
Twenty-six patients from the rehabilitation department and 
28 patients from the outpatient clinic were included between 
November 2013 and April 2014 (Figure 3). Together, these 
54 patients completed 2,928 of the 2,992 diary cards (97.9% 
completeness) during a mean participation period of 55.4 
(±SD 25.1) days. One hundred and fifteen symptom-based 
exacerbations were reported by 42 patients, with a median 
duration of 6.0 (IQR 7.4) days. Twenty-nine event-based 
episodes were documented from 22 patients. There were 
four hospital admissions in three patients, and no deaths 
during the follow-up period. Table 1 shows the baseline 
characteristics and median number of exacerbations of the 
study population.
automated advice of aCCess
On 2,099 of the 2,928 days (71.7%), ACCESS provided one 
or more pieces of treatment advice. In 285 cases (9.7%), 
there was only the advice to measure again the next day, and 
in 544 cases (18.6%) there was no advice given, meaning 
that no symptom changes were reported that day. Figure 4 
shows that the advice to contact a health care professional 
was given on 1,493 days (51.0% of 2,928 days). The advice 
to be thoughtful about how to distribute one’s energy over 
the day was given most often, in 1,829 cases (62.5%). 
The advice to use breathing techniques was provided in 
1,285 cases (43.9%), the advice to maximize bronchodilator 
use was provided in 1,249 cases (42.7%), and the advice to 
use coughing techniques in 730 cases (24.9%).
Validity of aCCess advice compared 
to symptom-based exacerbations
Table 2 shows the cross-tabulation between the advice to 
contact a health care professional and the actual presence 
(the second day) of a symptom-based exacerbation. In 112 
of the 115 exacerbations, ACCESS advised to contact the 
health care professional, so sensitivity was 97.4% (95% CI 
92.0–99.3). Specificity was 65.6% (95% CI 63.5–67.6), 
????????????????????????????
???????????????????????
?????????????????????????????
??????????????? ???????????????
???????????????????????????????????????????
????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????
Figure 3 Flowchart of patient participation in the study.
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positive predictive value was 13.4% (95% CI 11.2–15.9), and 
negative predictive value was 99.8% (95% CI 99.3–99.9).
In-depth analyses were performed to examine the cases 
where the advice to contact a health care professional was 
given by ACCESS, but no symptom-based exacerbation 
turned out to have occurred (n=725). Figure 5 shows that the 
main reasons for ACCESS to advise patients to contact their 
health care provider were: 1) a drop in FEV
1
 of at least 10% 
compared to the patient’s personal best value; 2) increased 
fatigue in combination with a worsening of at least one major 
symptom for at least two consecutive days; and 3) increased 
dyspnea that day in combination with increased dyspnea 
and/or wheeze the previous day.
Validity of aCCess advice compared to 
event-based exacerbations
A total of 29 event-based exacerbations were documented 
(Table 3). For the event-based exacerbations, sensitivity of 
the ACCESS advice to contact a health care professional was 
96.6% (95% CI 80.4–99.8), specificity was 52.2% (95% CI 
37.1–66.9), positive predictive value was 56.0% (95% CI 
41.4–69.7), and negative predictive value was 96.0% (95% 
CI 77.7–99.8).
In one occasion, a course of prednisolone had been 
prescribed but ACCESS had not advised to contact a health 
care professional (Table 3). It turned out that this patient had 
started his study participation during an exacerbation, and on 
his first day, he reported minor symptoms and prednisolone 
was prescribed. The advice to contact a health care profes-
sional was given by ACCESS on the next day.
Discussion
In this study, we reported on the automatically provided 
treatment advice of the ACCESS software application, which 
aims to support COPD patients to take timely and adequate 
action in their self-management in case of symptom changes 
and exacerbations. We found that on the majority of days 
(71.7%), ACCESS provided one or more pieces of treatment 
advice to reduce symptom burden. In 51.0% of the cases, the 
advice was given to contact a health care professional that 
day. Hence, in 20.7% of all cases, ACCESS did not detect an 
(developing) exacerbation, but the pieces of advice – other 
than to contact a health care professional – were provided to 
lower the burden of day-to-day symptom fluctuations.
Next, we investigated the safety of ACCESS by examining 
the validity of its advice to contact a health care professional. 
The high sensitivity of this advice for both symptom- and 
Table 1 Baseline characteristics of the study population (n=54) 
represented in mean (sD), median (IQr), or frequency (%)
age, years (sD) 64.7 (8.6)
Male (%) 32 (59.3)
FeV1, liters
a (sD) 1.26 (0.6)
FeV1% predicted
a (sD) 44.4 (18.2)
BMI, kg/m2,a (sD) 26.2 (4.8)
Follow-up time, days (sD) 55.4 (25.1)
symptom-based exacerbation episodes per month (IQr) 1.1 (3.5)
event-based exacerbation episodes per month (IQr) 0.0 (0.7)
Note: an=44.
Abbreviations: IQr, interquartile range; BMI, body mass index; FeV1, forced 
expiratory volume in one second.
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Figure 4 representation of percentages of times each advice was provided by aCCess, based on 2,928 diary cards. On each day, more than one advice could be provided.
Abbreviation: aCCess, adaptive Computerized COPD exacerbation self-management support.
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event-based exacerbations (97.4% and 96.6%, respectively) 
showed that when an exacerbation is imminent, ACCESS 
is very likely to advise the patient to contact a health care 
professional. The high negative predictive value of the advice 
for both symptom- and event-based exacerbations (99.8% 
and 96.0%, respectively) showed that when ACCESS does 
not advise to contact a health care professional, there is a 
very low risk of an imminent exacerbation. Based on these 
results, we conclude that ACCESS’ advice to contact a health 
care professional is safe for patients to follow, because the 
chance of under-treatment of exacerbations seems negligible. 
However, specificity was moderate to low (65.6% and 52.2% 
for symptom- and event-based exacerbations, respectively) 
and positive predictive values were low (13.4% and 56.0% 
for symptom- and event-based exacerbations, respectively). 
This suggests that contact with a health care professional 
may not be needed in all the cases that ACCESS provides 
the advice. It should be noted that ACCESS has not been 
developed to replace the health care professional but to 
decrease patient delay in case of a developing exacerbation. 
Thus, part of the moderate to low specificity and low posi-
tive predictive value can be explained by the discrepancy 
between our reference standard (an exacerbation) and the 
aim of ACCESS’ advice: contact a health care professional 
to consult about alarming symptoms which may (or which 
may not) be caused by an exacerbation. Furthermore, some 
of these advice-triggering signs or symptoms were measures 
that were not included in the definition of a symptom-based 
Table 2 Cross-tabulation of symptom-based exacerbationsa vs the 
advice to contact a health care professional given by aCCess
Symptom-based exacerbation
Yes No Total
aCCess advice 
to contact a 
health care 
professional
Yes 112
13.4%
97.4%
725
86.6%
34.4%
837
100%
37.7%
no 3
0.2%
2.6%
1,382
99.8%
65.6%
1,385
100%
62.3%
Total 115
5.2%
100%
2,107
94.8%
100%
2,222
100%
100%
Note: aBased on the second consecutive day of worsening of at least one major 
symptom (dyspnea, sputum purulence, sputum amount) and one minor symptom 
(cold, wheeze, sore throat, cough).5,24,25
Abbreviation: aCCess, adaptive Computerized COPD exacerbation self-
management support.
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Figure 5 representation of reasons for aCCess’ advice to contact a health care professional, in the absence of a symptom-based exacerbation (n=725). In each event, more 
than one reason may apply.
Notes: 1) a worsening of at least 2 consecutive days in two or more major symptoms (dyspnea, sputum purulence, sputum amount) or a change in any one major symptom 
plus a cold and/or wheeze and/or sore throat and/or cough and/or fatigue; 2) dyspnea and/or wheeze and dyspnea and/or wheeze the previous day; 3) decrease in FeV1 is 
10% or more of personal best; 4) increased dyspnea and increased bronchodilator use; 5) decrease in spO2 is 4% or more of personal best; 6) risk calculation of Bayesian 
network is higher than 85%; 7) a worsening of two or more major symptoms (dyspnea, sputum purulence, sputum amount); 8) fifth consecutive day that advice “measure 
again tomorrow” (indication of worsening of any symptom) is given; 9) increased dyspnea and fear of increased dyspnea; 10) third day of increased wheeze and increased 
bronchodilator use; 11) any one major symptom (dyspnea, sputum purulence, sputum amount) and fever (see also Figure 2).
Abbreviation: aCCess, adaptive Computerized COPD exacerbation self-management support; spO2, peripheral capillary oxygen saturation; FeV1, forced expiratory 
volume in one second.
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exacerbation that we used as reference standard, such as a 
drop in FEV
1
 and peripheral capillary oxygen saturation val-
ues, or fatigue. This definitely has influenced specificity and 
positive predictive value, but the advice still may have been 
clinically relevant, since these parameters are mentioned in 
the literature as possible indicators of an exacerbation.26–31 
Still, the expert panel may also have been overly cautious in 
assigning the pieces of advice in the decision model, which 
is understandable because of heterogeneity of symptoms and 
onset of exacerbations.
Comparison to other literature
In most other telehealth systems that have been developed 
for COPD in recent years, a health care professional moni-
tors the input of patients actively, and patients are contacted 
in case of an imminent exacerbation.32–38 These health care 
professionals may be cautious in their monitoring too. More-
over, these systems require continuous availability of health 
care professionals, and patients may come to rely on the 
health care professional to contact them in case of alarming 
symptoms instead of the other way around. Thus, instead of 
improving patient’s self-management and reducing patient 
delay, the latter may even increase. To our knowledge, only 
one other electronic support system provides automated 
advice to patients with COPD.39 This Web-based application 
advises on the start of prednisolone or antibiotics in case of 
an exacerbation, whereas our system provides various pieces 
of self-management advice right from the onset of symptom 
changes, even before an exacerbation can be established. 
Besides, so far as we know, the validity of the Web-based 
application has not been tested yet. We found a high rate of 
symptom-based exacerbations (ie, a median of 1.1 exacerba-
tions per month) compared to other studies.5,14,23 This may be 
caused both by the inclusion of patients who were likely to 
be frequent exacerbators and our methodological approach 
to count a new episode when there were 2 days without 
exacerbation or missing days preceding the entry. In our 
view, this approach resembles a home situation best, where 
we aim to improve early recognition and patients should be 
advised at any time of a symptom worsening.
strengths and limitations
Patients recorded the exacerbation-related data daily on 
paper diary cards that were compiled weekly. This resulted 
in a very high completeness of data (97.9%) and reduced the 
potential for recall bias. Also, the use of paper diary cards 
instead of using ACCESS as software application prevented 
potential bias caused by differences in digital skills among 
our study population. The mean follow-up time in our study 
was shorter than planned. Our initial plan was to include the 
pulmonary rehabilitation patients in the first week after start-
ing rehabilitation and follow them for the complete duration 
of the program, which is 12 weeks. However, many patients 
were not enrolled in our study until week 4 of the rehabilita-
tion program, resulting in a shorter follow-up period than the 
expected 12 weeks. Still, we found a high rate of symptom-
based exacerbations, because of the inclusion of patients 
who were known by their health care professional to have a 
high risk of exacerbations. We did not perform a sample size 
calculation, although this is recommended in the STARD 
2015 guideline,40 as we conducted secondary analyses on data 
that were obtained for the cross-validation of the Bayesian 
network model. Furthermore, at this moment, there is no 
other tool with a well-studied diagnostic accuracy with 
which we can compare ACCESS. The validity of ACCESS 
was tested in a population that was recruited in an outpatient 
clinic and in our pulmonary rehabilitation department and 
were prone to have exacerbations. This could have caused 
selection bias and it may be questioned whether our results 
can be generalized to a less severe COPD population with a 
lower risk of having exacerbations, such as in primary care. 
However, we previously demonstrated that in primary care 
also, the frequency of symptom-based exacerbations among 
patients with COPD is high.41
Future research
Further research to assess the clinical effectiveness of 
this support is ongoing (ClinicalTrials.gov Identifier: 
NCT02553096). If we find that moderate specificity results 
in unnecessary health care utilization, extended analyses 
are needed to investigate if specificity could be increased, 
without losing the high sensitivity.
Table 3 Cross-tabulation of event-based exacerbationsa vs the 
advice to contact a health care professional given by aCCess
Event-based exacerbation
Yes No Total
aCCess advice to 
contact a health 
care professional
Yes 28
56.0%
96.6%
22
44.0%
47.8%
50
100%
66.7%
no 1b
4.0%
3.4%
24
96.0%
52.2%
25
100%
33.3%
Total 29
38.7%
100%
46
61.3%
100%
75
100%
100%
Notes: aexacerbations treated with a course of antibiotics and/or prednisolone or 
resulted in hospitalization. bPatient started a course of prednisolone on his first day 
of study participation, reporting only minor symptoms that day.
Abbreviation: aCCess, adaptive Computerized COPD exacerbation self-
management support.
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Conclusion
In nearly three-quarters of the cases, ACCESS provided 
one or more of the following pieces of self-management 
advice – increase bronchodilator use, use breathing tech-
niques, use coughing techniques, be thoughtful on how to 
distribute one’s energy over the day, and to contact a health 
care professional. This shows that ACCESS supports patients 
in their self-management of day-to-day symptom variations. 
Additionally, this study showed that ACCESS provided the 
advice to contact a health care professional on time, ie, on 
the second day of an exacerbation, with high sensitivity and 
negative predictive value, and thus appears to be a safe tool 
to use at home for patients with COPD. ACCESS has not 
been developed to replace the health care professional but 
to assist patients to take timely and adequate action in case 
of symptom worsening. In this way, ACCESS may improve 
self-management, decrease patient delay in seeking medical 
treatment when an exacerbation is imminent, and reduce 
disease burden by COPD.
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Supplementary materials
Previous steps in the development 
of aCCess
The aim of the ACCESS system is to support COPD patients 
in exacerbation self-management by detecting exacerbations 
and providing tailored and timely treatment advice.
Building and optimizing the Bayesian network model
van der Heijden et al1 have described the first develop-
mental phase of ACCESS (Figures S1 and S2, Step 1). In 
summary, a Bayesian network model was constructed based 
on expert opinion of two pulmonary physicians, who pro-
vided relevant parameters based on their clinical experience 
and contemporary literature. A Bayesian network model is a 
flexible probabilistic model that can compute the probability 
of the presence of a disease based on available symptoms, 
also in case of missing data, and predictions can be per-
sonalized by entering patient-specific data. Based on the 
expert-driven model and available data, a data-driven model 
was created and compared to the occurrence of symptom-
based exacerbations.1 This resulted in a risk prediction of 
exacerbations based on 12 yes or no questions which are 
complemented with measurements of peripheral capillary 
oxygen saturation (SpO
2
), forced expiratory volume in one 
second (FEV
1
), and body temperature. Furthermore, a pilot 
study among patients with COPD was performed to examine 
usability of the smart phone and sensors.1
Primary aim of the study described in the current paper 
was to gather data for a cross-validation procedure to opti-
mize and test the Bayesian network model to automatically 
detect exacerbations. The data were divided in six groups 
of nine randomly selected patients. In each of the six cross-
validity checks, the model learned to identify exacerbations 
based on the entries of the five training sets and was then 
tested for diagnostic accuracy on the sixth set. Gold standard 
were symptom-based exacerbations. The final model, result-
ing from the cross-validation procedure, showed an area 
under curve of the receiver operating curve of 91.4% (95% 
CI 90.3–92.5; Figure S3).
After the cross-validation procedure, a cutoff point of 
85% was chosen to indicate when an exacerbation was at 
hand. Any risk calculation beyond this point should lead 
to an automatic advice of ACCESS to contact a health care 
professional or start a course of prednisolone.
Development and integration of automatic treatment 
advices
The next goal was to formulate treatment advice based on 
the risk calculation of the Bayesian network model to be 
given automatically by ACCESS. However, when discussing 
the matter in detail with clinicians, it became clear that 
self-management advice could not solely be based on the 
risk calculation of ACCESS. To decide in which specific 
situation what advice should be given by ACCESS, clinical 
Figure S1 schematic presentation of the aCCess system.
Abbreviation: aCCess, adaptive Computerized COPD exacerbation self-management support.
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expertise was used (Figure S2, Step 2). Expert involvement 
was realized in a three-step procedure: 1) an expert panel 
consisting of a pulmonary physician, a general practitioner, 
and a clinical psychologist discussed with which symp-
toms they wanted a patient to take what action, based on 
their clinical experience and contemporary guidelines for 
COPD exacerbation management; 2) various health care 
professionals – pulmonary physicians, pulmonary nurses, 
general practitioners, practice nurses – provided the advices 
they would give in four standardized cases on paper; and 
3) these advices were then discussed by the expert panel 
and minor adjustments were made to the decision model.
In contrast to what we had previously anticipated, the 
expert panel focused on its clinical judgment, rather than 
using the risk calculation of the Bayesian network model as 
a base for the advices. This was perhaps inevitable in many 
cases, since several advices are initiated based on specific 
symptoms. Eventually, a cutoff point of the risk calculation 
of the Bayesian network model was chosen to underlie the 
expert panel’s decision model for automatic advice. This 
cutoff point was set at 85%, with a sensitivity of 65.8% 
(95% CI 62.4–69.0), specificity of 91.5% (95% CI 90.2–92.6), 
positive predictive value of 75.0% (95% CI 71.6–78.1), and 
negative predictive value of 87.3% (95% CI 85.8–88.6). 
When this cutoff point is reached, ACCESS will always 
provide the advice to contact a health care professional.
The advices are personalized by the patient’s health 
care professional, who enters the patient’s FEV
1
 and SpO
2
 
values in the system as reference values, and adds specific 
medication instructions for maximal bronchodilator use. 
Specific advices can be blocked for a patient, if his health 
care professional deems this best. For instance, if the patient 
Figure S2 schematic overview of the development of the adaptive Computerized COPD exacerbation self-management support (aCCess) system.
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Figure S3 rOC curve of cutoff values of the Bayesian network model’s risk 
calculation to identify a symptom-based exacerbation.
Abbreviations: rOC, receiver operating curve; aUC, area under the curve.
has not been taught coughing techniques, the advice to 
use coughing techniques would be irrelevant, maybe even 
confusing.
As a last step in the developmental phase, we have 
examined in the current study if patients are advised safely 
and correctly, by comparing the clinically most important 
ACCESS advice – “Contact a health care professional 
today” – with a symptom-based and an event-based defi-
nition of exacerbations (Step 4). For a clinical evaluation 
of ACCESS, a randomized controlled trial is in progress, 
comparing the effect of ACCESS with the effect of a written 
action plan on exacerbation time (Step 5).
Reference
1. van der Heijden M, Lucas PJ, Lijnse B, Heijdra YF, Schermer TR. An 
autonomous mobile system for the management of COPD. J Biomed 
Inform. 2013;46(3):458–469.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 1
2-
No
v-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
